News

Replimune (REPL) stock plummeted on Tuesday after the biotechnology company received a Complete Response Letter (CRL) from ...
Replimune's RP1 treatment for advanced melanoma faces FDA rejection due to trial design issues, despite promising results ...
Replimune faces FDA hurdles for RP1, an innovative melanoma treatment, as it seeks a path forward after receiving a complete ...
The FDA cited trial design concerns and lack of substantial evidence in denying approval for Replimune’s biologics license application in advanced melanoma.
The FDA has issued a complete response letter to Replimune indicating it is unable to approve the biologics license ...
Erin Andrews, the renowned sports broadcaster, has bravely shared her decade-long fertility struggles, including multiple IVF rounds and surrogacy cha ...
Over the past three decades, tremendous achievements have been made in the treatment of patients with multiple myeloma (MM), ...
In a wholly new approach to cancer treatment, Northwestern University biomedical engineers have doubled the effectiveness of ...
When it comes to living in a high-sun state like Arizona, a simple skin check can mean the difference between life and death ...
Patients receiving subcutaneous daratumumab have less chair time and premedication than those receiving IV formulation, says ...